ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
A Supportive Membership Offer While You Plan Your Next Step
Being made redundant, or finding yourself between roles for any reason, can be an unsettling time. It can also be an important moment to reconnect with your professional community, explore new opportunities, and invest in your next step.
The apparent tectonic shift in the global bio-innovation landscape has markedly accelerated, and 2025-26 is providing One Nucleus members with exciting opportunities and huge challenges like never before. Adapting to maintain the key role of convener, supporter, ally and compass for members navigating these changes has led One Nucleus to invest in developing a new toolbox to help our members.
Tagomics is a Cambridge-based biotechnology company developing a next-generation multi-omic platform to transform how disease and drug safety are understood, measured and monitored.
Our proprietary technology extracts genetic, epigenetic and fragmentomic information from circulating cell-free DNA. Combined with advanced bioinformatics and machine learning, it enables deep biological insight across applications including drug safety, organ health monitoring and cancer detection.
🔹 Project Manager
🔹 Senior/Principal Assay Development Scientist (Genetic Code Expansion)
🔹 Research Associate (tRNA)
🔹 Lead Scientist (Novel Biomolecule Process Development)
Amsbio has launched a range of synthetic cell mimic products that eliminate the variability, fragility, and operational inefficiency inherent in traditional flow cytometry biological and polystyrene bead controls.
Researchers in pharmaceutical companies, biotechnology firms, CRO’s, clinical diagnostics and academic centres have long sought access to mass-produced cell mimics that contain rare biomarkers and are stable over the long term for the development of targeted therapies.